Haemonetics HAE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Haemonetics’s reported figures.
Based on trailing twelve months.
The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's return on equity?
- Haemonetics (HAE) reported return on equity of 19.3% in Q4 2025.
- How has Haemonetics's return on equity changed year-over-year?
- Haemonetics's return on equity increased by 37.2% year-over-year, from 14.1% to 19.3%.
- What is the long-term trend for Haemonetics's return on equity?
- Over 4 years (2021 to 2025), Haemonetics's return on equity has grown at a 11.8% compound annual growth rate (CAGR), from 12.1% to 18.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.